Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (1): 129-138    DOI: 10.31083/j.ejgo.2021.01.5423
Original Research Previous articles | Next articles
Classical HLA class I antigen downregulation and abnormal HLA-G expression in ovarian cancer
Min Jong Song1, Suk Il Jang2, Hyon Jee Yoon1, Eun Young Ki3, Joon Mo Lee2, Soo Young Hur2, *()
1Department of Obstetrics and Gynecology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 07345 Seoul, Korea
2Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 06591 Seoul, Korea
3Department of Obstetrics and Gynecology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 34943 Daejeon, Korea
Download:  PDF(7717KB)  ( 39 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To elucidate the potential role of HLA-G and classical HLA class I molecules in ovarian cancer, we researched their patterns of expression in benign and malignant ovarian tumors. Methods: In 10 benign and 33 malignant ovarian tumor tissues, HLA-G expression was determined both at the mRNA level by reverse transcriptase-polymerase chain reaction and immunohistochemical staining. The expression of classical HLA class I heavy chains were determined immunohistochemically. Results: Immunohistochemical analysis revealed the expression of HLA-G molecules in 27 of the 33 (81.8%) ovarian cancers but in none of the benign ovarian tumors. Classical HLA class I antigen expression was down-regulated in 25 out of the 33 (75.8%) ovarian cancers and in only 1 of the 10 benign ovarian tumors. HLA-G expression and classical HLA class I antigen down-regulation were related to disease stage (Spearman's rho = 0.468, P = 0.001; Spearman's rho = -0.392, P = 0.005). Conclusions: Our results reveal that abnormal expression of HLA-G and down-regulation of classical HLA class I antigen in ovarian cancer may be one of the mechanisms by which cancer cells may escape host's immune system.
Key words:  Ovarian cancer      Immune escape      Human leukocyte antigen class I molecule      Human leukocyte antigen-G     
Submitted:  31 October 2019      Revised:  14 September 2020      Accepted:  15 September 2020      Published:  15 February 2021     
*Corresponding Author(s):  bitsugar74@gmail.com; hursy@catholic.ac.kr (Soo Young Hur)   

Cite this article: 

Min Jong Song, Suk Il Jang, Hyon Jee Yoon, Eun Young Ki, Joon Mo Lee, Soo Young Hur. Classical HLA class I antigen downregulation and abnormal HLA-G expression in ovarian cancer. European Journal of Gynaecological Oncology, 2021, 42(1): 129-138.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.01.5423     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I1/129

[1] Tadahiro Shoji, Kotoka Kikuchi, Hayato Kogita, Nanako Jonai, Hidetoshi Tomabechi, Akiko Kudoh, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba. New treatment strategy for ovarian cancer with a BRCA gene mutation[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 1-9.
[2] Sigit Purbadi, Kade Yudi Saspriyana. Primary debulking surgery of advanced epithelial ovarian cancer in developing countries: challenges and expectations[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 26-29.
[3] Ece Gumusoglu, Tuba Gunel, Mohammad Kazem Hosseini, Nogayhan Seymen, Taylan Senol, Uğur Sezerman, Samet Topuz, Kılıç Aydınlı. The importance of dysregulated miRNAs on ovarian cysts and epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 66-72.
[4] Joseph J. Noh, Kyue-Hee Choi, Hyun-Soo Kim, Jeong-Won Lee. Port site implantation of clear cell carcinoma after laparoscopic ovarian cystectomy[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 174-178.
[5] Francesco Plotti, Bartolone Martina, Terranova Corrado, Luvero Daniela, Scaletta Giuseppe, Gatti Alessandra, Benedetti Panici Pierluigi, Angioli Roberto. Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic review of literature[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 889-896.
[6] Irina Esteves-Krasteva, José Ángel Minguez, José María Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Gabriel Zozaya-Larequi, Juan Luis Alcázar, Matías Jurado. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 906-912.
[7] Sefa Kurt, Selim Kandemir, Onur Yavuz, Meral Koyuncuoglu, Emine Cagnur Ulukus, Murat Celiloglu. Persistent tubal epithelium in ovaries after salpingectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 919-923.
[8] Haci Ozturk Sahin, Zelal Aydin, Ibrahim Ugras Toktas, Cetin Toraman, Ilkbal Temel Yuksel, Alper Seyhan, Ozgur Akbayir. Clinical and prognostic value of pre-operative systemic inflammatory markers in clinical course and prognosis of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 924-930.
[9] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta, Miwa Yasaka, Hiroko Machida, Masae Ikeda, Masako Shida, Takeshi Hirasawa, Mikio Mikami. Usefulness of laparoscopic restaging surgery for patients diagnosed with apparent early ovarian/fallopian tubal cancer by a prior surgery, a case control observational study in a single institute in Japan[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 960-968.
[10] Fatih Kose, Songül Alemdaroğlu, Hüseyin Mertsoylu, Ali Ayberk Beşen, Ozan Cem Güler, Seda Yüksel Şimşek, Gürcan Erbay, Cem Önal, Hüsnü Çelik. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 989-995.
[11] R van de Vrie, E van Werkhoven, M J Rutten, J D Asseler, H S van Meurs, D E Werter, M R Buist, A.H. Zwinderman, C A R Lok, P.M.M. Bossuyt, G G Kenter, P Tajik. Validation of a treatment-selection rule for patients with advanced stage ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 1023-1030.
[12] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[13] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[14] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[15] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
No Suggested Reading articles found!